Quick Answer
IGC Pharma, Inc. reported Net Income of -$7.12 million for fiscal year 2025.
IGC Pharma, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$7.12M | +45.2% |
| 2024 | -$13.00M | -13.0% |
| 2023 | -$11.51M | +23.4% |
| 2022 | -$15.02M | -70.4% |
| 2021 | -$8.81M | -20.5% |
| 2020 | -$7.32M | -78.5% |
| 2019 | -$4.10M | -129.4% |
| 2018 | -$1.79M | +4.4% |
| 2017 | -$1.87M | +33.5% |
| 2016 | -$2.81M | +39.1% |
| 2015 | -$4.61M | -52.7% |
| 2014 | -$3.02M | -34.2% |
| 2013 | -$2.25M | +70.9% |
| 2012 | -$7.75M | +61.7% |
| 2011 | -$20.24M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.82M | -6.1% | -13.9% |
| June 30, 2025 | -$1.60M | +32.8% | +12.6% |
| December 31, 2024 | -$1.83M | +67.3% | -6.5% |
| September 30, 2024 | -$1.72M | +29.9% | +27.8% |
| June 30, 2024 | -$2.38M | -14.6% | +57.5% |
| December 31, 2023 | -$5.59M | -148.5% | -128.0% |
| September 30, 2023 | -$2.45M | -0.4% | -18.1% |
| June 30, 2023 | -$2.08M | +25.5% | +7.7% |
- IGC Pharma, Inc. showed an increase of +45.2% in Net Income compared to the prior fiscal year.
- Over the 2011–2025 period, IGC Pharma, Inc.’s net income has grown by 64.8% (from -$20.24 million to -$7.12 million).
- The most recent figure is from IGC Pharma, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 27, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: